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Objective:  The  pathology  of  the salivary  glands  focuses  on  that  of  the parotid  gland.  The purpose  of this
study  is  to clarify  and  explain  the  epidemiological  features  of  parotid  tumors  in  a Senegalese  context,  to
highlight  the  importance  of clinical  examination  when  access  to complementary  investigations  is limited,
to discuss  respective  indications  and  ﬁnally  to describe  certain  aspects  of treatment  in our  context.
Materials  and  methods:  This  retrospective  study  of  114  cases  of  parotidectomy  spans  16  years,  from  1992
to  2007.  It was  performed  in  the  ENT  department  of  University  Hospital  of  Fann,  Senegal.  All  patients  oper-
ated on  for chronic  mass  of the  parotid  region  for whom  histological  results  were  available  when  initially
included.  Benign  swellings  were  subsequently  excluded.  The  study  parameters  were  epidemiological,
clinical,  paraclinical  and  surgical.
Results:  The  114  parotidectomies  showed  a predominance  of  benign  tumours:  63  procedures  (55.26%)
essentially  concerned  pleomorphic  adenoma;  30  cases  (26.31%)  concerned  malignant  tumours,  mainly
parotid  adenocarcinoma.  There  were  21  cases  of  benign  swelling  (18.4%).  The  study  focused  on  the  series
of  93 cases  of benign  and  malignant  tumours  of the  parotid  gland.  Both  sexes  were  affected  similarly.  All
age groups  were  concerned,  from  5  to 89  years.  A  total  of  97%  of patients  underwent  surgery:  conservative
total  parotidectomy  in  75.51%  of cases.
Conclusion:  Although  there  are  features  speciﬁc  to  the  local  context,  the  epidemiological  proﬁle  of parotid
tumours  is  well-known.  Indications  for complementary  investigations  are  discussed,  as  availability  in
Senegal  is  restricted,  highlighting  the  important  role  of  clinical  examination  in  the management  of  parotid
tumours.
. Introduction
Salivary gland tumours are rare, representing 3–5% of head and
eck tumours [1,2]. Pleomorphic adenoma or mixed tumour is the
ost common benign form (85%). Deﬁnitive diagnosis of parotid
umour requires parotidectomy. Preoperative diagnosis is founded
n ﬁne-needle aspiration cytology and medical imaging. MRI  is the
adiologic examination of choice in case of suspected malignancy.
he present report is a proﬁle analysis of a series of 114 parotid
land tumours collated between 1992 and 2007 in the ENT and head
nd neck surgery department of Dakar university hospital, Senegal.. Material and methods
A retrospective study, performed in the ENT and head and neck
urgery department of the Aristide Le Dantec university hospital
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of Dakar (Senegal) between January 1st, 1992 and December 31st,
2007 (i.e., 16 years), recruited 216 parotidectomy patients. One
hundred and fourteen ﬁles included histologic analysis: 63 benign
tumours, 30 malignant tumours and 21 benign swellings. Benign
swelling comprised acute or chronic inﬂammatory glandular
hypertrophy: cyst, parotiditis, intraparotid adenitis, tuberculosis,
lithiasis and benign lympho-epithelial lesions; these cases were
excluded from analysis. The 93 cases of parotid tumour were
included in the study.
The study thus included all patients undergoing parotid gland
surgery for histologically proven parotid tumour. Epidemiological
(age and gender), clinical (time to and reason for consultation),
paraclinical (ultrasonography, CT, histology) and therapeutic data
were analyzed.
3. Results3.1. Age and gender
Mean age was  40.9 years (range, 5–89 yrs). There was a clear
female predominance: 61 cases (65.6%; F/M sex-ratio, 1.9).
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Table 1
Tumor distribution by location.
Location Number (percentage)
Sublobular 22 (49%)
Retroparotid 13 (29%)
Parotid- submaxillary 4 (9%)
Cheek 1 (2.22%)
Left side 26 (45.62%)
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Intra-oral expression 4 (9%)
.2. Clinical data
Mean time to consultation was 4.3 years (1 month to 20 years).
arotid swelling at admission was systematic, and the princi-
al presenting symptom. Nineteen patients (20.4%) complained of
ntense parotid pain; these included 12 with parotid cancer and 7
ith benign tumour.
Seven of the 40 assessable patients (17.5%) showed peripheral
acial palsy. On physical examination, swelling was found to be lob-
lar in 22 cases (49%). Table 1 shows the distribution of parotid
umour locations. Swellings ranged from 1 to 15 cm along the long
xis, mainly between 2 and 6 cm (in 17 of the 30 cases where it was
ecorded: 57%). Ten malignant tumours were measured, of which
 were between 6 and 10 cm.  The swelling was pain-free in 74
atients (79.5% of tumours). Consistence varied: 19 (61.29%) were
rm, and 9 (29.3%) hard. Fourteen were mobile (70% of the 20 cases
n which consistence was recorded). Covering skin was ulcerated
n 7 cases (7.5%). Eleven patients (12%) had lymphadenopathies.
.3. Paraclinical data
CT was performed in 3 cases (3.22%), for strong suspicion of
alignancy and because the patients were able to pay for the exam-
nation. Ultrasonography was requested in 20 patients (21.5%).
one of the series underwent MRI.
.4. SurgeryNinety of the 93 parotid tumour patients were operated on
97%); the 3 in whom surgery was contraindicated underwent
iopsy (3.2%). There were 37 conservative total parotidectomies
able 2
umour distribution by histologic type, gender and age.
Gender 
Male n (%) Female n (
Type of tumour
Benign 21 (65.62%) 42 (68.85%
Malignant 11 (34.37%) 19 (31.84%
Histologic type
Pleomorphic adenoma 15 (71.42%) 26 (61.90%
Whartin’s tumour 4 (19.04%) 3 (7.14%) 
Oxyphil cell adenoma (oncocytoma) 1 (2.38%) 
Other  adenomas 1 (4.76%) 4 (9.52%) 
Hemangioma 0 2 (4.76%) 
Hemangiopericytoma 0 1 (2.38%) 
Neuroma 1 (2.38%) 
Lymphangioma 1 (4.76%) 0 
Lipoma 4 (9.52%) 
Adenocarcinoma 5 (45.45%) 3 (15.78%)
Cylindroma (Adenoid cystic carcinoma) 1 (9.09%) 7 (36.84%)
Mucoepidermoid carcinoma 1 (9.09%) 4 (21.05%)
Squamous cell carcinoma 3 (27.27%) 2 (10.52%)
Anaplastic (undifferentiated) carcinoma 1 (9.09%) 0 
Oncocytic carcinoma 0 1 (5.26%) 
Malignant melanoma 0 1 (5.26%) 
Lymphoma 0 1 (5.26%) logy, Head and Neck diseases 132 (2015) 9–12
(75.51%), 6 non-conservative total parotidectomies (12.24%), and
6 superﬁcial or exofacial parotidectomies (12.24%). The superﬁ-
cial lobe was  the most frequently involved (61.2%). Parotidectomy
was extended in 3 cases (3.3%) to the masseter and pterygoid mus-
cles and the mandible. Lymph-node resection, performed in 6 cases
(6.4%), was  complete radical in 1 case, modiﬁed radical in 1, func-
tional in 2 and triangular selective in 2.
3.5. Histology
The present series of 93 parotid tumour patients showed a pre-
dominance of benign forms, with 63 cases (67.74%), versus 30
malignancies (32.25%). There were, moreover, 21 parotid swellings
among the patients undergoing parotidectomy during the study
period.
Female subjects were more affected than males: 61 (65.6%),
versus 32 (34.40%). The rates of benign and malignant tumour
according to gender were similar: 68.85% benign tumours in
females (42/61) and 65.62% in males (21/32); 31.14% malignant
tumours in females (19/61) and 34.37% in males (11/32).
Mean age at onset of benign tumour was  41.5 years (range,
17–70 years) in males, and 37.7 years (6–67 years) in females, and
for malignant tumour 41.45 years (5–69 years) and 47 years (6–89
years) respectively.
Pleomorphic adenoma was  the most frequent form of benign
tumour at 65.07%, followed by Whartin’s tumour (17.46%). The
rates for hemangioma and lipoma were respectively 3.17% and
6.34%. The most frequent forms of malignant tumour were ade-
nocarcinoma (26.66%) and adenoid cystic carcinoma (26.66%)
(Table 2).
4. Discussion
The parotid is the most important gland in the salivary system,
and also the one most frequently involved by every type of tumour,
regardless of age or sex [2–4]. The present study describes the
epidemiological characteristics of 93 parotid tumours (epithelial,
mesenchymatous and lymphoid), analyzing sex-ratios, frequency
and histology. Results showed later onset in malignant as compared
to benign tumour, as consistently found in the literature [2,3,5,6].
Benign parotid tumour affected both sexes comparably: 68.85%
of parotid tumours in females and 65.05% in males. These ﬁndings
Total n M/F  Mean age (years)
%) Male Female
) 63 0.5 41.52 37.71
) 30 0.57 41.45 47
) 41 41 41.69
7 46 35.6
1 No data
5 48 43.25
2 18
1 No data
1 No data
1 No data
4 31.75
 8 37.6 54.6
 8 44 39.71
 5 51 58.75
 5 58 80.5
1 51
1 45
1 64
1 1 month
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Dantec à propos de 218 cas colligés de janvier 1981 à décembre 2000; 2001
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gree with older reports [2,4–8]; only Akkari’s series [9] stands out,
eporting male predominance.
The clinical presentation of parotid tumours is rich and varied.
ocations may  be lobular, submaxillary, retroparotid, cheek, nuchal
r sometimes intra-oral. Their clinical latency explains the long
nterval (mean, 4.3 years) between onset and consultation found
n our part of the world, comparable to that reported by Musani
n Pakistan [6]; in Brazil, Takahama reported 3.3 years [5], with
horter times reported in Tunisia by Brahim [3] and Spain by Her-
ando [4]. This delay explains the spectacular forms encountered
n our context, with giant tumours of 1.5 kg. Fear, neglect, primary
onsultation in traditional medicine and lack of ﬁnancial means are
ll contributing factors.
The need for complementary examinations (modern medi-
al imaging) in apparently benign, mobile, superﬁcial tumours
s debatable in our patients’ usual economic situation [7]. Even
o, contrast-enhanced cervical and parotid CT or high-resolution
ltrasonography should be standardized [4], providing useful pre-
perative indications: site, size and associated lymphadenopathy
nd/or metastasis. Senegal was equipped with its ﬁrst public hospi-
al MRI  scanner in 2007, but the patients in the present series were
ot able to take advantage of this. Between 1992 and 2007, diagno-
is and treatment were guided by clinical signs: rate of evolution,
mmune status, pain, tumour mobility with respect to underly-
ng structures, cutaneous aspect (induration, inﬁltration, cutaneous
xtension), lymphadenopathy palpation, and associated peripheral
acial palsy or lockjaw. Any of these signs should raise suspicion
f parotid cancer, whereas a pain-free, mobile, well-delineated
umour is probably benign. In some forms, signs are poorly con-
ributive to diagnosis, and imaging then has its role to play.
In suspected malignancy, MRI  locates the tumour, checks cap-
ule integrity, enables delineation and detects lymphadenopathies;
t is thus highly contributive [4].
In our context, painstaking clinical examination, screening for
igns of malignancy, and CT were the preoperative elements guid-
ng diagnosis.
Fine-needle aspiration cytology is now widely used, with
9–97% precision [10]. The main problem is to have a trained
nd experienced cytologist available. It is not part of our current
ractice, for 3 reasons: it does not prevent surgery; it does not
ffect conservative total parotidectomy; and, above all, the num-
er of pathologists working in Senegal up to 2007 restricted access
o this procedure. It is, however, of obvious interest: it avoids
utting certain patients on waiting-lists that are already long, gives
ome forecast of probable surgery time (associating lymph-node
esection or not), and provides information for the patient.
Histologically, benign tumours were more frequent (67.74% of
arotid tumours as a whole). All published series [2,5–7] agree on
ercentages in the 60–74.5% range.
Pleomorphic adenoma was consistently the most frequent form
f benign parotid tumour, at 65.07%. This is in line with reports by
ubhashaj [2] (80.23%), Hernando [4] (54%), Takabama [5] (66.5%)
nd Musani [6] (83.55%). Whartin’s tumour was  the second most
requent (11,1%), as in the above series [2,5,6] (8.23%, 25.20% and
.89%, respectively), and is constantly increasing in our country:
iop et al. [7] reported 3 cases (4.6%) in a series of 80 parotid
umours between 1975 and 1990; Sene [11] reported 2 cases, in
he same clinical context as the present report and Diop’s but for a
ifferent period (1981–2000). The present series contained 7 cases
f papillary cystadenolymphoma, the frequency of which has been
onstantly increasing since the mid-1970s; one explanation may
e the increase in chronic smoking observed over the same period,
specially in women.
Unlike the 2009 Brazilian, 2009 Pakistani and 2007 Tunisian
eries [5,6,9], in which mucoepidermoid carcinoma was the main
alignant form in the present series, adenocarcinoma and adenoid
[
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cystic carcinoma were the most frequent, at 26.6% of parotid malig-
nancies; mucoepidermoid carcinoma was in third place at 16.6%.
These rates are similar to those reported by Subhashaj [2], where
adenoid cystic carcinoma was the most frequent form of parotid
cancer; for Hernando [4], the most frequent was malignant acinic
cell adenocarcinoma. These variations may be geographical in
nature, but in fact remain unexplained [12].
Twenty-four percent of all salivary tumours are of epithelial ori-
gin; the others are non-epithelial: hemangioma, lymphangioma,
lipoma and malignant lymphoma. The latter were rare in the
present series (see Table 2), in agreement with Takahama’s Brazil-
ian [5], Musani’s Pakistani and Brahim’s Tunisian series [3].
Surgery is indicated when feasible. Our maximalist attitude,
with 75.51% conservative total parotidectomy, is, in the Sene-
galese context, due to the difﬁculty of access to complementary
examinations, the small number of cytologists, lack of frozen-
section examination and problems of follow-up of patients living in
areas remote from our ENT department [11]. Exofacial parotidec-
tomy is reserved for cysts and lipomas in our current practice,
and pleomorphic adenoma was mainly managed by conser-
vative total parotidectomy to reduce the risk of recurrence
[13–17].
5. Conclusion
The proﬁle of parotid tumour is rich and complex, as are the
cell populations of the gland itself. In the present series, pleomor-
phic adenoma was the most frequent benign form, followed by
Whartin’s tumour, which is constantly progressing in our country,
where onset of malignancy is at a more advanced age. The inade-
quacy of our paraclinical arsenal in terms of ﬁne-needle aspiration
cytology and frozen-section examination imposes a maximalist
surgical attitude toward parotid tumour.
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